Jump to content
Cell Line Development

Open Forum on NGS-Based Cell Line Development

Industry Workshop on the Present and Future of NGS in CLD, co-hosted by Boehringer Ingelheim

Register to Attend the Event

Virtual Industry Workshop on April 29th, 2021

The aim of this exclusive event is to bring together key experts to facilitate knowledge sharing around the challenges and opportunities in NGS-based cell line characterization and multi-omics data integration.

We are delighted to announce that our host will be Dr. Jan Visser, Vice President of Bioprocess Development Biologicals at Boehringer Ingelheim. 

Please register through the link above to receive a calendar invite for this invitation only event.

We look forward to welcoming you at the event. In the meantime, please have a look at our exciting agenda below!



EDTCESTTuesday, April 29, 2021
9:00 am3:00 pmWelcome and Introduction to the Participants
Jan Visser, Vice President Bioprocess Development Biologicals, Boehringer Ingelheim
Thomas Hartsch, 
Head of Selector Business at Genedata
9:05 am3:05 pmCell Line Characterization 2.0: Implementation of Sequence Variant Analysis via RNA-seq and Future Perspectives
Benjamin Lindner, Senior Data Scientist, Boehringer Ingelheim
9:30 am3:30 pmNext Generation CLD: Integration of Multi-omics Data and Applications
Kitty Agarwal, Principal Scientist, Biologics Process Development, Bristol-Myers Squibb
9:50 am3:50 pmDEMO: CRISPR for Cell Line Engineering
Devon Ryan, Scientific Consultant, Genedata
10:00 am4:00 pmComparison of NGS-based Methods for the Characterization of Gene Knockouts
Rico Uhler, Data Scientist, Cell Line Development, Octapharma Biopharmacueticals
10:20 am4:20 pmDEMO: Simplified Verification of Integration Sites in CLD
Sean Powell, Scientific Consultant, Genedata
10:30 am4:30 pmOpen Discussion
All participants, moderated by Genedata
11:00 am5:00 pmEnd of Day

Disclaimer:  “The purpose of our gathering and discussions is to start a pre-competitive R&D collaboration and discuss best practices using NGS-based biosafety to identify adventitious agents during biopharma R&D.  We consider our discussions to be pre-competitive in nature as the best practices can be used very broadly in the industry.  Please keep the conversation to this topic and refrain from bringing up topics that could be considered anti-competitive under antitrust/competition laws, such as pricing.”